KEVIN CHARLES GORMAN Insider Trading $NBIX NEUROCRINE BIOSCIENCES INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for KEVIN CHARLES GORMAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of KEVIN CHARLES GORMAN. KEVIN CHARLES GORMAN is Chief Executive Officer in NEUROCRINE BIOSCIENCES INC ($NBIX) and President and CEO in NEUROCRINE BIOSCIENCES INC ($NBIX) and Vice President Business Dev. in NEUROCRINE BIOSCIENCES INC ($NBIX) and Director in Xencor Inc ($XNCR).
KEVIN CHARLES GORMAN in NEUROCRINE BIOSCIENCES INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of KEVIN CHARLES GORMAN: Chief Executive Officer, President and CEO, Vice President Business Dev.
Holdings: 443,249 shares
Current Value: $19,325,656
Latest Transaction: Feb 09 2021
$NBIX Market Capitalization: $3.81B
$NBIX Previous Close: $43.60
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of KEVIN CHARLES GORMAN in NEUROCRINE BIOSCIENCES INC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 17,269 | 0 | 17,269 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 117.63 | 103,609 | 12,187,527 | 103,609 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 116.72 | 3,248 | 379,089 | 452,972 | 456.2 K to 453 K (-0.71 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 116.74 | 4,343 | 506,999 | 450,051 | 454.4 K to 450.1 K (-0.96 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 116.79 | 2,875 | 335,775 | 446,144 | 449 K to 446.1 K (-0.64 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 114.16 | 2,422 | 276,504 | 443,249 | 445.7 K to 443.2 K (-0.54 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.65 | 164,801 | 1,425,529 | 0 | |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 143,449 | 1,242,268 | 0 | |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 110.22 | 164,801 | 18,164,778 | 441,071 | 605.9 K to 441.1 K (-27.20 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.65 | 164,801 | 1,425,529 | 605,872 | 441.1 K to 605.9 K (+37.36 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 110.21 | 143,449 | 15,809,098 | 441,071 | 584.5 K to 441.1 K (-24.54 %) |
| Jan 12 2021 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 143,449 | 1,242,268 | 584,520 | 441.1 K to 584.5 K (+32.52 %) |
| Nov 16 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 90.78 | 3,390 | 307,748 | 441,071 | 444.5 K to 441.1 K (-0.76 %) |
| Aug 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 118.91 | 3,390 | 403,101 | 438,021 | 441.4 K to 438 K (-0.77 %) |
| Apr 28 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 99.45 | 2,906 | 289,016 | 434,971 | 437.9 K to 435 K (-0.66 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 103.36 | 3,248 | 335,696 | 432,357 | 435.6 K to 432.4 K (-0.75 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 23,081 | 0 | 23,081 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 102.90 | 145,698 | 14,992,324 | 145,698 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 101.56 | 4,343 | 441,068 | 429,436 | 433.8 K to 429.4 K (-1.00 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 103.09 | 2,422 | 249,693 | 425,529 | 428 K to 425.5 K (-0.57 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 103.08 | 3,027 | 312,033 | 423,351 | 426.4 K to 423.4 K (-0.71 %) |
| Aug 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 32.99 | 3,031 | 99,993 | 0 | |
| Aug 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 32.99 | 3,031 | 99,993 | 420,628 | 417.6 K to 420.6 K (+0.73 %) |
| Aug 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 32.99 | 3,031 | 99,993 | 0 | |
| Aug 13 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 32.99 | 3,031 | 99,993 | 420,628 | 417.6 K to 420.6 K (+0.73 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 26,330 | 228,018 | 143,449 | |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 2,759 | 23,893 | 169,779 | |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 50,911 | 440,889 | 172,538 | |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 95.64 | 26,330 | 2,518,154 | 417,597 | 443.9 K to 417.6 K (-5.93 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 26,330 | 228,018 | 443,927 | 417.6 K to 443.9 K (+6.31 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 95.12 | 2,759 | 262,440 | 417,597 | 420.4 K to 417.6 K (-0.66 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 2,759 | 23,893 | 420,356 | 417.6 K to 420.4 K (+0.66 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 95.15 | 50,911 | 4,844,380 | 417,597 | 468.5 K to 417.6 K (-10.87 %) |
| Aug 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 50,911 | 440,889 | 468,508 | 417.6 K to 468.5 K (+12.19 %) |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 24,677 | 0 | 24,677 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 81.05 | 133,345 | 10,807,612 | 133,345 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 84.23 | 4,096 | 344,986 | 417,597 | 421.7 K to 417.6 K (-0.97 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 88.28 | 1,992 | 175,853 | 413,943 | 415.9 K to 413.9 K (-0.48 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 88.12 | 2,497 | 220,042 | 410,185 | 412.7 K to 410.2 K (-0.61 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 88.10 | 3,125 | 275,321 | 408,082 | 411.2 K to 408.1 K (-0.76 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 32.99 | 864 | 28,503 | 3,031 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 19.59 | 7,142 | 139,912 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 32.99 | 864 | 28,503 | 3,031 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.65 | 10,199 | 88,221 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 19.59 | 7,142 | 139,912 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 16,551 | 143,332 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.65 | 10,199 | 88,221 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 5.76 | 23,168 | 133,448 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 8.66 | 16,551 | 143,332 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 32.99 | 864 | 28,503 | 404,957 | 404.1 K to 405 K (+0.21 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 5.76 | 23,168 | 133,448 | 0 | |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 19.59 | 7,142 | 139,912 | 404,093 | 397 K to 404.1 K (+1.80 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 32.99 | 864 | 28,503 | 404,957 | 404.1 K to 405 K (+0.21 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.65 | 10,199 | 88,221 | 396,951 | 386.8 K to 397 K (+2.64 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 19.59 | 7,142 | 139,912 | 404,093 | 397 K to 404.1 K (+1.80 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 16,551 | 143,332 | 386,752 | 370.2 K to 386.8 K (+4.47 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.65 | 10,199 | 88,221 | 396,951 | 386.8 K to 397 K (+2.64 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 5.76 | 23,168 | 133,448 | 370,201 | 347 K to 370.2 K (+6.68 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 8.66 | 16,551 | 143,332 | 386,752 | 370.2 K to 386.8 K (+4.47 %) |
| Jun 29 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 5.76 | 23,168 | 133,448 | 370,201 | 347 K to 370.2 K (+6.68 %) |
| May 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 5.76 | 126,832 | 730,552 | 0 | |
| May 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 80.75 | 126,832 | 10,241,735 | 347,033 | 473.9 K to 347 K (-26.77 %) |
| May 03 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 5.76 | 126,832 | 730,552 | 473,865 | 347 K to 473.9 K (+36.55 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 18,400 | 0 | 18,400 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 18,400 | 0 | 18,400 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 81.49 | 104,200 | 8,491,258 | 104,200 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 5.76 | 100,000 | 576,000 | 126,832 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Payment of Exercise | F | 82.48 | 4,091 | 337,426 | 347,033 | 351.1 K to 347 K (-1.17 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 80.07 | 100,000 | 8,006,620 | 342,874 | 442.9 K to 342.9 K (-22.58 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 5.76 | 100,000 | 576,000 | 442,874 | 342.9 K to 442.9 K (+29.17 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 83.47 | 2,858 | 238,543 | 342,874 | 345.7 K to 342.9 K (-0.83 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 83.08 | 3,125 | 259,621 | 339,482 | 342.6 K to 339.5 K (-0.91 %) |
| Jan 18 2018 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 78.89 | 3,750 | 295,820 | 336,357 | 340.1 K to 336.4 K (-1.10 %) |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 2.59 | 21,739 | 56,304 | 0 | |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 53.23 | 21,739 | 1,157,167 | 332,607 | 354.3 K to 332.6 K (-6.13 %) |
| May 03 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 2.59 | 21,739 | 56,304 | 354,346 | 332.6 K to 354.3 K (+6.54 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 51.23 | 306 | 15,676 | 332,607 | 332.9 K to 332.6 K (-0.09 %) |
| Apr 13 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 50.41 | 19,290 | 972,409 | 332,913 | 352.2 K to 332.9 K (-5.48 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | M | 2.59 | 64,161 | 166,177 | 21,739 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 0.00 | 33,400 | 0 | 33,400 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Option Exercise | A | 43.24 | 207,400 | 8,967,976 | 207,400 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Buy | M | 2.59 | 64,161 | 166,177 | 314,703 | 250.5 K to 314.7 K (+25.61 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 43.18 | 3,010 | 129,972 | 250,542 | 253.6 K to 250.5 K (-1.19 %) |
| Feb 06 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 42.55 | 3,125 | 132,969 | 247,802 | 250.9 K to 247.8 K (-1.25 %) |
| Jan 18 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 40.65 | 3,750 | 152,438 | 244,677 | 248.4 K to 244.7 K (-1.51 %) |
| Jan 12 2017 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Chief Executive Off ... | Sell | S | 43.28 | 3,750 | 162,300 | 240,927 | 244.7 K to 240.9 K (-1.53 %) |
| Dec 23 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | M | 2.59 | 9,100 | 23,569 | 85,900 | |
| Dec 23 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Buy | M | 2.59 | 9,100 | 23,569 | 237,177 | 228.1 K to 237.2 K (+3.99 %) |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 0.00 | 35,750 | 0 | 35,750 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 35.99 | 109,100 | 3,926,509 | 109,100 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 0.00 | 23,000 | 0 | 23,000 | |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 38.04 | 3,125 | 118,875 | 228,077 | 231.2 K to 228.1 K (-1.35 %) |
| Jan 21 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 46.70 | 3,750 | 175,125 | 224,952 | 228.7 K to 225 K (-1.64 %) |
| Jan 13 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 44.17 | 3,750 | 165,638 | 221,202 | 225 K to 221.2 K (-1.67 %) |
| Oct 19 2015 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 47.77 | 33,500 | 1,600,295 | 217,452 | 251 K to 217.5 K (-13.35 %) |
| Mar 24 2015 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | M | 2.59 | 40,000 | 103,600 | 95,000 | |
| Mar 24 2015 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 41.53 | 40,000 | 1,661,200 | 188,452 | 228.5 K to 188.5 K (-17.51 %) |
| Mar 24 2015 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Buy | M | 2.59 | 40,000 | 103,600 | 228,452 | 188.5 K to 228.5 K (+21.23 %) |
| Mar 03 2004 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Vice President Busi ... | Grant | A | 55.15 | 2,000 | 110,300 | 57,996 | 56 K to 58 K (+3.57 %) |
| Feb 12 2004 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Vice President Busi ... | Sell | S | 57.37 | 2,000 | 114,740 | 55,996 | 58 K to 56 K (-3.45 %) |
| Feb 12 2004 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Vice President Busi ... | Sell | S | 57.38 | 2,000 | 114,760 | 57,996 | 60 K to 58 K (-3.33 %) |
| Feb 12 2004 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | Vice President Busi ... | Sell | S | 57.29 | 2,000 | 114,580 | 59,996 | 62 K to 60 K (-3.23 %) |
Page: 1